Global Osteoporosis Market, Patients, Companies & Forecast
Osteoporosis is a silent disease until it is complicated by fractures that occur following minimal trauma or, in some cases, with no trauma. Globally Osteoporosis is expected to be more than US$ 40 Billion market by 2019. China and India together have close to 80% of osteoporosis patients worldwide. Whereas this in case of hip fracture cases both the countries China and India have more than 60% patients. But when we study Osteoporosis in market terms then United States controls the highest market share followed by China and Japan. Amgen and Eli Lilly are two dominant players in Osteoporosis drugs market.
This is the 2nd edition report on Osteoporosis by Renub Research. Report titled 'Global Osteoporosis Market, Patients, Companies & Forecast' provides a comprehensive analysis of the current state of this market and likely future evolution over the next 5 years. This 124 page report with 89 Figures and 8 Tables studies the Worldwide Osteoporosis market from 6 view points:
1) Osteoporosis Patients & Forecast
2) Hip fracture Patients & Forecast
3) Osteoporosis Market & Forecast
4) Country Wise Osteoporosis level of Awareness, Guidelines & Policy
5) Country Wise Reimbursement of Medication
6) Company Wise Osteoporosis Drugs Sales & Forecast
All the 10 Countries studied in the report are as follows
1) India
2) China
3) Japan
4) Korea
5) Brazil
6) Russia
7) United Kingdom
8) France
9) Germany
10) United States
Worldwide Osteoporosis – Company Wise Drugs Sales Analysis (2010 – 2019)
1) Merck
2) Sanofi
3) Novartis
4) Eli Lilly
5) Amgen
Data Sources
This report is built using data and information sourced from proprietary databases, primary and secondary research and in–house analysis by Renub Research team of industry experts.
Primary sources include industry surveys and telephonic interviews with industry experts.
Secondary sources information and data has been collected from various printable and non–printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Government Agencies, Magazines, Newspapers, Trade associations, Books, Industry Portals, Industry Associations and access to more than 500 paid databases.
This is the 2nd edition report on Osteoporosis by Renub Research. Report titled 'Global Osteoporosis Market, Patients, Companies & Forecast' provides a comprehensive analysis of the current state of this market and likely future evolution over the next 5 years. This 124 page report with 89 Figures and 8 Tables studies the Worldwide Osteoporosis market from 6 view points:
1) Osteoporosis Patients & Forecast
2) Hip fracture Patients & Forecast
3) Osteoporosis Market & Forecast
4) Country Wise Osteoporosis level of Awareness, Guidelines & Policy
5) Country Wise Reimbursement of Medication
6) Company Wise Osteoporosis Drugs Sales & Forecast
All the 10 Countries studied in the report are as follows
1) India
2) China
3) Japan
4) Korea
5) Brazil
6) Russia
7) United Kingdom
8) France
9) Germany
10) United States
Worldwide Osteoporosis – Company Wise Drugs Sales Analysis (2010 – 2019)
1) Merck
2) Sanofi
3) Novartis
4) Eli Lilly
5) Amgen
Data Sources
This report is built using data and information sourced from proprietary databases, primary and secondary research and in–house analysis by Renub Research team of industry experts.
Primary sources include industry surveys and telephonic interviews with industry experts.
Secondary sources information and data has been collected from various printable and non–printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Government Agencies, Magazines, Newspapers, Trade associations, Books, Industry Portals, Industry Associations and access to more than 500 paid databases.
1. EXECUTIVE SUMMARY
2. WORLDWIDE OSTEOPOROSIS PATIENTS POPULATION ANALYSIS
2.1 Worldwide Osteoporosis Patients Population (2010 – 2019)
2.2 Worldwide Hip Fracture Patients Population (2010 – 2019)
3. WORLDWIDE OSTEOPOROSIS MARKET (2010 – 2019)
4. WORLDWIDE OSTEOPOROSIS SHARE ANALYSIS
4.1 Worldwide Osteoporosis Patients Population Share (2010 – 2019)
4.2 Worldwide Hip Fracture Patients Population Share (2010 – 2019)
4.3 Worldwide Osteoporosis Market Share (2010 – 2019)
4.4 Worldwide Osteoporosis Drugs Company Market Share (2010 – 2019)
5. INDIA
5.1 India Osteoporosis Patients Population (2010 – 2019)
5.2 India Hip Fracture Patients Population (2010 – 2019)
5.3 India Osteoporosis Market (2010 – 2019)
5.4 Level of Awareness
5.5 Fracture Registries
5.6 Government Policies
5.7 Guidelines
5.8 Reimbursement of Medication
6. CHINA
6.1 China Osteoporosis Patients Population (2010 – 2019)
6.2 China Hip Fracture Patients Population (2010 – 2019)
6.3 China Osteoporosis Market (2010 – 2019)
6.4 Level of Awareness
6.5 Fracture Registries
6.6 Government Policies
6.7 Guidelines
6.8 Reimbursement of Medication
7. JAPAN
7.1 Japan Osteoporosis Patients Population (2010 – 2019)
7.2 Japan Hip Fracture Patients Population (2010 – 2019)
7.3 Japan Osteoporosis Market (2010 – 2019)
7.4 Level of Awareness
7.5 Fracture Registries
7.6 Government Policies
7.7 Guidelines
7.8 Reimbursement of Medication
8. KOREA
8.1 Korea Osteoporosis Patients Population (2010 – 2019)
8.2 Korea Hip Fracture Patients Population (2010 – 2019)
8.3 Korea Osteoporosis Market (2010 – 2019)
8.4 Level of Awareness
8.5 Fracture Registries
8.6 Government Policies
8.7 Guidelines
8.8 Reimbursement of Medication
9. BRAZIL
9.1 Brazil Osteoporosis Patients Population (2010 – 2019)
9.2 Brazil Hip Fracture Patients Population (2010 – 2019)
9.3 Brazil Osteoporosis Market (2010 – 2019)
9.4 Level of Awareness
9.5 Guidelines & Policy
9.6 Reimbursement Policy
10. RUSSIA
10.1 Russia Osteoporosis Patients Population (2010 – 2019)
10.2 Russia Hip Fracture Patients Population (2010 – 2019)
10.3 Russia Osteoporosis Market (2010 – 2019)
10.4 Level of Awareness
10.5 Government Policy
10.6 Guidelines
10.7 Reimbursement
11. UNITED KINGDOM
11.1 United Kingdom Osteoporosis Patients Population (2010 – 2019)
11.2 United Kingdom Hip Fracture Patients Population (2010 – 2019)
11.3 United Kingdom Osteoporosis Market (2010 – 2019)
11.4 Guidelines
11.5 Reimbursement Policy
12. FRANCE
12.1 France Osteoporosis Patients Population (2010 – 2019)
12.2 France Hip Fracture Patients Population (2010 – 2019)
12.3 France Osteoporosis Market (2010 – 2019)
12.4 Guidelines
12.5 Reimbursement Policy
13. GERMANY
13.1 Germany Osteoporosis Patients Population (2010 – 2019)
13.2 Germany Hip Fracture Patients Population (2010 – 2019)
13.3 Germany Osteoporosis Market (2010 – 2019)
13.4 Guidelines
13.5 Reimbursement Policy
14. UNITED STATES
14.1 United States Osteoporosis Patients Population (2010 – 2019)
14.2 United States Hip Fracture Patients Population (2010 – 2019)
14.3 United States Osteoporosis Market (2010 – 2019)
14.4 Policy
14.5 Guidelines
14.6 Reimbursement Policy
15. GROWTH DRIVER
15.1 Widespread Vitamin D Deficiency & Low Calcium Intake
15.2 Globally Increasing Ageing Population & Life Expectancy
16. CHALLENGES
16.1 Lack of Reimbursement / Other Restrictions for Reimbursement
16.2 Limited Access of Diagnostic Tools & Low Levels of Public and Health Professional Awareness
16.3 Lack of Government Osteoporosis Policy, Guidelines & National Health Priority in Asia Pacific Countries
17. KEY PLAYERS OSTEOPOROSIS DRUGS SALES & FORECAST
17.1 Merck Osteoporosis Drugs Sales (2010 – 2019)
17.2 Sanofi Osteoporosis Drugs Sales (2010 – 2019)
17.3 Novartis Osteoporosis Drugs Sales (2010 – 2019)
17.4 Eli Lilly Osteoporosis Drugs Sales (2010 – 2019)
17.5 Amgen Osteoporosis Drugs Sales (2010 – 2019)
2. WORLDWIDE OSTEOPOROSIS PATIENTS POPULATION ANALYSIS
2.1 Worldwide Osteoporosis Patients Population (2010 – 2019)
2.2 Worldwide Hip Fracture Patients Population (2010 – 2019)
3. WORLDWIDE OSTEOPOROSIS MARKET (2010 – 2019)
4. WORLDWIDE OSTEOPOROSIS SHARE ANALYSIS
4.1 Worldwide Osteoporosis Patients Population Share (2010 – 2019)
4.2 Worldwide Hip Fracture Patients Population Share (2010 – 2019)
4.3 Worldwide Osteoporosis Market Share (2010 – 2019)
4.4 Worldwide Osteoporosis Drugs Company Market Share (2010 – 2019)
5. INDIA
5.1 India Osteoporosis Patients Population (2010 – 2019)
5.2 India Hip Fracture Patients Population (2010 – 2019)
5.3 India Osteoporosis Market (2010 – 2019)
5.4 Level of Awareness
5.5 Fracture Registries
5.6 Government Policies
5.7 Guidelines
5.8 Reimbursement of Medication
6. CHINA
6.1 China Osteoporosis Patients Population (2010 – 2019)
6.2 China Hip Fracture Patients Population (2010 – 2019)
6.3 China Osteoporosis Market (2010 – 2019)
6.4 Level of Awareness
6.5 Fracture Registries
6.6 Government Policies
6.7 Guidelines
6.8 Reimbursement of Medication
7. JAPAN
7.1 Japan Osteoporosis Patients Population (2010 – 2019)
7.2 Japan Hip Fracture Patients Population (2010 – 2019)
7.3 Japan Osteoporosis Market (2010 – 2019)
7.4 Level of Awareness
7.5 Fracture Registries
7.6 Government Policies
7.7 Guidelines
7.8 Reimbursement of Medication
8. KOREA
8.1 Korea Osteoporosis Patients Population (2010 – 2019)
8.2 Korea Hip Fracture Patients Population (2010 – 2019)
8.3 Korea Osteoporosis Market (2010 – 2019)
8.4 Level of Awareness
8.5 Fracture Registries
8.6 Government Policies
8.7 Guidelines
8.8 Reimbursement of Medication
9. BRAZIL
9.1 Brazil Osteoporosis Patients Population (2010 – 2019)
9.2 Brazil Hip Fracture Patients Population (2010 – 2019)
9.3 Brazil Osteoporosis Market (2010 – 2019)
9.4 Level of Awareness
9.5 Guidelines & Policy
9.6 Reimbursement Policy
10. RUSSIA
10.1 Russia Osteoporosis Patients Population (2010 – 2019)
10.2 Russia Hip Fracture Patients Population (2010 – 2019)
10.3 Russia Osteoporosis Market (2010 – 2019)
10.4 Level of Awareness
10.5 Government Policy
10.6 Guidelines
10.7 Reimbursement
11. UNITED KINGDOM
11.1 United Kingdom Osteoporosis Patients Population (2010 – 2019)
11.2 United Kingdom Hip Fracture Patients Population (2010 – 2019)
11.3 United Kingdom Osteoporosis Market (2010 – 2019)
11.4 Guidelines
11.5 Reimbursement Policy
12. FRANCE
12.1 France Osteoporosis Patients Population (2010 – 2019)
12.2 France Hip Fracture Patients Population (2010 – 2019)
12.3 France Osteoporosis Market (2010 – 2019)
12.4 Guidelines
12.5 Reimbursement Policy
13. GERMANY
13.1 Germany Osteoporosis Patients Population (2010 – 2019)
13.2 Germany Hip Fracture Patients Population (2010 – 2019)
13.3 Germany Osteoporosis Market (2010 – 2019)
13.4 Guidelines
13.5 Reimbursement Policy
14. UNITED STATES
14.1 United States Osteoporosis Patients Population (2010 – 2019)
14.2 United States Hip Fracture Patients Population (2010 – 2019)
14.3 United States Osteoporosis Market (2010 – 2019)
14.4 Policy
14.5 Guidelines
14.6 Reimbursement Policy
15. GROWTH DRIVER
15.1 Widespread Vitamin D Deficiency & Low Calcium Intake
15.2 Globally Increasing Ageing Population & Life Expectancy
16. CHALLENGES
16.1 Lack of Reimbursement / Other Restrictions for Reimbursement
16.2 Limited Access of Diagnostic Tools & Low Levels of Public and Health Professional Awareness
16.3 Lack of Government Osteoporosis Policy, Guidelines & National Health Priority in Asia Pacific Countries
17. KEY PLAYERS OSTEOPOROSIS DRUGS SALES & FORECAST
17.1 Merck Osteoporosis Drugs Sales (2010 – 2019)
17.2 Sanofi Osteoporosis Drugs Sales (2010 – 2019)
17.3 Novartis Osteoporosis Drugs Sales (2010 – 2019)
17.4 Eli Lilly Osteoporosis Drugs Sales (2010 – 2019)
17.5 Amgen Osteoporosis Drugs Sales (2010 – 2019)
LIST OF FIGURES
Figure 2–1: Worldwide – Osteoporosis Patients Population (Thousand), 2010 – 2014
Figure 2–2: Worldwide – Forecast for Osteoporosis Patients Population (Thousand), 2015 – 2019
Figure 2–3: Worldwide – Distribution of Hip Fracture Risk in Men, 2012
Figure 2–4: Worldwide – Distribution of Hip Fracture Risk in Women, 2012
Figure 2–5: Worldwide – Hip Fracture Patients Population (Thousand), 2010 – 2014
Figure 2–6: Worldwide – Forecast for Hip Fracture Patients Population (Thousand), 2015 – 2019
Figure 3–1: Worldwide – Osteoporosis Market (Million US$), 2010 – 2014
Figure 3–2: Worldwide – Forecast for Osteoporosis Market (Million US$), 2015 – 2019
Figure 4–1: Worldwide – Osteoporosis Patients Population Share (Percent), 2010 – 2014
Figure 4–2: Worldwide – Forecast for Osteoporosis Patients Population Share (Percent), 2015 – 2019
Figure 4–3: Worldwide – Hip Fracture Patients Population Share (Percent), 2010 – 2014
Figure 4–4: Worldwide – Forecast for Hip Fracture Patients Population Share (Percent), 2015 – 2019
Figure 4–5: Worldwide – Osteoporosis Market Share (Percent), 2010 – 2014
Figure 4–6: Worldwide – Forecast for Osteoporosis Market Share (Percent), 2015 – 2019
Figure 4–7: Worldwide – Osteoporosis Drugs Company Market Share (Percent), 2010 – 2014
Figure 4–8: Worldwide – Forecast for Osteoporosis Drugs Company Market Share (Percent), 2015 – 2019
Figure 5–1: India – Osteoporosis Patients Population (Thousand), 2010 – 2014
Figure 5–2: India – Forecast for Osteoporosis Patients Population (Thousand), 2015 – 2019
Figure 5–3: India – Hip Fracture Patients Population (Thousand), 2010 – 2014
Figure 5–4: India – Forecast for Hip Fracture Patients Population (Thousand), 2015 – 2019
Figure 5–5: India – Osteoporosis Market (Million US$), 2010 – 2014
Figure 5–6: India – Forecast for Osteoporosis Market (Million US$), 2015 – 2019
Figure 6–1: China – Osteoporosis Patients Population (Thousand), 2010 – 2014
Figure 6–2: China – Forecast for Osteoporosis Patients Population (Thousand), 2015 – 2019
Figure 6–3: China – Hip Fracture Patients Population (Thousand), 2010 – 2014
Figure 6–4: China – Forecast for Hip Fracture Patients Population (Thousand), 2015 – 2019
Figure 6–5: China – Osteoporosis Market (Million US$), 2010 – 2014
Figure 6–6: China – Forecast for Osteoporosis Market (Million US$), 2015 – 2019
Figure 7–1: Japan – Osteoporosis Patients Population (Thousand), 2010 – 2014
Figure 7–2: Japan – Forecast for Osteoporosis Patients Population (Thousand), 2015 – 2019
Figure 7–3: Japan – Hip Fracture Patients Population (Thousand), 2010 – 2014
Figure 7–4: Japan – Forecast for Hip Fracture Patients Population (Thousand), 2015 – 2019
Figure 7–5: Japan – Osteoporosis Market (Million US$), 2010 – 2014
Figure 7–6: Japan – Forecast for Osteoporosis Market (Million US$), 2015 – 2019
Figure 8–1: Korea – Osteoporosis Patients Population (Thousand), 2010 – 2014
Figure 8–2: Korea – Forecast for Osteoporosis Patients Population (Thousand), 2015 – 2019
Figure 8–3: Korea – Hip Fracture Patients Population (Thousand), 2010 – 2014
Figure 8–4: Korea – Forecast for Hip Fracture Patients Population (Thousand), 2015 – 2019
Figure 8–5: Korea – Osteoporosis Market (Million US$), 2010 – 2014
Figure 8–6: Korea – Forecast for Osteoporosis Market (Million US$), 2015 – 2019
Figure 9–1: Brazil – Osteoporosis Patients Population (Thousand), 2010 – 2014
Figure 9–2: Brazil – Forecast for Osteoporosis Patients Population (Thousand), 2015 – 2019
Figure 9–3: Brazil – Hip Fracture Patients Population (Thousand), 2010 – 2014
Figure 9–4: Brazil – Forecast for Hip Fracture Patients Population (Thousand), 2015 – 2019
Figure 9–5: Brazil – Osteoporosis Market (Million US$), 2010 – 2014
Figure 9–6: Brazil – Forecast for Osteoporosis Market (Million US$), 2015 – 2019
Figure 10–1: Russia – Osteoporosis Patients Population (Thousand), 2010 – 2014
Figure 10–2: Russia – Forecast for Osteoporosis Patients Population (Thousand), 2015 – 2019
Figure 10–3: Russia – Hip Fracture Patients Population (Thousand), 2010 – 2014
Figure 10–4: Russia – Forecast for Hip Fracture Patients Population (Thousand), 2015 – 2019
Figure 10–5: Russia – Osteoporosis Market (Million US$), 2010 – 2014
Figure 10–6: Russia – Forecast for Osteoporosis Market (Million US$), 2015 – 2019
Figure 10–7: Russia – Level of Awareness (Percent), 2010
Figure 11–1: United Kingdom – Osteoporosis Patients Population (Thousand), 2010 – 2014
Figure 11–2: United Kingdom – Forecast for Osteoporosis Patients Population (Thousand), 2015 – 2019.
Figure 11–3: United Kingdom – Hip Fracture Patients Population (Thousand), 2010 – 2014
Figure 11–4: United Kingdom – Forecast for Hip Fracture Patients Population (Thousand), 2015 – 2019
Figure 11–5: United Kingdom – Osteoporosis Market (Million US$), 2010 – 2014
Figure 11–6: United Kingdom – Forecast for Osteoporosis Market (Million US$), 2015 – 2019
Figure 12–1: France – Osteoporosis Patients Population (Thousand), 2010 – 2014
Figure 12–2: France – Forecast for Osteoporosis Patients Population (Thousand), 2015 – 2019
Figure 12–3: France – Hip Fracture Patients Population (Thousand), 2010 – 2014
Figure 12–4: France – Forecast for Hip Fracture Patients Population (Thousand), 2015 – 2019
Figure 12–5: France – Osteoporosis Market (Million US$), 2010 – 2014
Figure 12–6: France – Forecast for Osteoporosis Market (Million US$), 2015 – 2019
Figure 13–1: Germany – Osteoporosis Patients Population (Thousand), 2010 – 2014
Figure 13–2: Germany – Forecast for Osteoporosis Patients Population (Thousand), 2015 – 2019
Figure 13–3: Germany – Hip Fracture Patients Population (Thousand), 2010 – 2014
Figure 13–4: Germany – Forecast for Hip Fracture Patients Population (Thousand), 2015 – 2019
Figure 13–5: Germany – Osteoporosis Market (Million US$), 2010 – 2014
Figure 13–6: Germany – Forecast for Osteoporosis Market (Million US$), 2015 – 2019
Figure 14–1: United States – Osteoporosis Patients Population (Thousand), 2010 – 2014
Figure 14–2: United States – Forecast for Osteoporosis Patients Population (Thousand), 2015 – 2019
Figure 14–3: United States – Hip Fracture Patients Population (Thousand), 2010 – 2014
Figure 14–4: United States – Forecast for Hip Fracture Patients Population (Thousand), 2015 – 2019
Figure 14–5: United States – Osteoporosis Market (Million US$), 2010 – 2014
Figure 14–6: United States – Forecast for Osteoporosis Market (Million US$), 2015 – 2019
Figure 15–1: Worldwide – Ageing Population & Forecast (Million), 2010 – 2050
Figure 15–2: Worldwide – Life Expectancy (Year), 1990, 2000 & 2012
Figure 17–1: Merck – Osteoporosis Drugs Sales (Million US$), 2010 – 2014
Figure 17–2: Merck – Forecast for Osteoporosis Drugs Sales (Million US$), 2015 – 2019
Figure 17–3: Sanofi – Osteoporosis Drugs Sales (Million US$), 2010 – 2014
Figure 17–4: Sanofi – Forecast for Osteoporosis Drugs Sales (Million US$), 2015 – 2019
Figure 17–5: Novartis – Osteoporosis Drugs Sales (Million US$), 2010 – 2014
Figure 17–6: Novartis – Forecast for Osteoporosis Drugs Sales (Million US$), 2015 – 2019
Figure 17–7: Eli Lilly – Osteoporosis Drugs Sales (Million US$), 2010 – 2014
Figure 17–8: Eli Lilly – Forecast for Osteoporosis Drugs Sales (Million US$), 2015 – 2019
Figure 17–9: Amgen – Osteoporosis Drugs Sales (Million US$), 2010 – 2014
Figure 17–10: Amgen – Forecast for Osteoporosis Drugs Sales (Million US$), 2015 – 2019
Figure 2–1: Worldwide – Osteoporosis Patients Population (Thousand), 2010 – 2014
Figure 2–2: Worldwide – Forecast for Osteoporosis Patients Population (Thousand), 2015 – 2019
Figure 2–3: Worldwide – Distribution of Hip Fracture Risk in Men, 2012
Figure 2–4: Worldwide – Distribution of Hip Fracture Risk in Women, 2012
Figure 2–5: Worldwide – Hip Fracture Patients Population (Thousand), 2010 – 2014
Figure 2–6: Worldwide – Forecast for Hip Fracture Patients Population (Thousand), 2015 – 2019
Figure 3–1: Worldwide – Osteoporosis Market (Million US$), 2010 – 2014
Figure 3–2: Worldwide – Forecast for Osteoporosis Market (Million US$), 2015 – 2019
Figure 4–1: Worldwide – Osteoporosis Patients Population Share (Percent), 2010 – 2014
Figure 4–2: Worldwide – Forecast for Osteoporosis Patients Population Share (Percent), 2015 – 2019
Figure 4–3: Worldwide – Hip Fracture Patients Population Share (Percent), 2010 – 2014
Figure 4–4: Worldwide – Forecast for Hip Fracture Patients Population Share (Percent), 2015 – 2019
Figure 4–5: Worldwide – Osteoporosis Market Share (Percent), 2010 – 2014
Figure 4–6: Worldwide – Forecast for Osteoporosis Market Share (Percent), 2015 – 2019
Figure 4–7: Worldwide – Osteoporosis Drugs Company Market Share (Percent), 2010 – 2014
Figure 4–8: Worldwide – Forecast for Osteoporosis Drugs Company Market Share (Percent), 2015 – 2019
Figure 5–1: India – Osteoporosis Patients Population (Thousand), 2010 – 2014
Figure 5–2: India – Forecast for Osteoporosis Patients Population (Thousand), 2015 – 2019
Figure 5–3: India – Hip Fracture Patients Population (Thousand), 2010 – 2014
Figure 5–4: India – Forecast for Hip Fracture Patients Population (Thousand), 2015 – 2019
Figure 5–5: India – Osteoporosis Market (Million US$), 2010 – 2014
Figure 5–6: India – Forecast for Osteoporosis Market (Million US$), 2015 – 2019
Figure 6–1: China – Osteoporosis Patients Population (Thousand), 2010 – 2014
Figure 6–2: China – Forecast for Osteoporosis Patients Population (Thousand), 2015 – 2019
Figure 6–3: China – Hip Fracture Patients Population (Thousand), 2010 – 2014
Figure 6–4: China – Forecast for Hip Fracture Patients Population (Thousand), 2015 – 2019
Figure 6–5: China – Osteoporosis Market (Million US$), 2010 – 2014
Figure 6–6: China – Forecast for Osteoporosis Market (Million US$), 2015 – 2019
Figure 7–1: Japan – Osteoporosis Patients Population (Thousand), 2010 – 2014
Figure 7–2: Japan – Forecast for Osteoporosis Patients Population (Thousand), 2015 – 2019
Figure 7–3: Japan – Hip Fracture Patients Population (Thousand), 2010 – 2014
Figure 7–4: Japan – Forecast for Hip Fracture Patients Population (Thousand), 2015 – 2019
Figure 7–5: Japan – Osteoporosis Market (Million US$), 2010 – 2014
Figure 7–6: Japan – Forecast for Osteoporosis Market (Million US$), 2015 – 2019
Figure 8–1: Korea – Osteoporosis Patients Population (Thousand), 2010 – 2014
Figure 8–2: Korea – Forecast for Osteoporosis Patients Population (Thousand), 2015 – 2019
Figure 8–3: Korea – Hip Fracture Patients Population (Thousand), 2010 – 2014
Figure 8–4: Korea – Forecast for Hip Fracture Patients Population (Thousand), 2015 – 2019
Figure 8–5: Korea – Osteoporosis Market (Million US$), 2010 – 2014
Figure 8–6: Korea – Forecast for Osteoporosis Market (Million US$), 2015 – 2019
Figure 9–1: Brazil – Osteoporosis Patients Population (Thousand), 2010 – 2014
Figure 9–2: Brazil – Forecast for Osteoporosis Patients Population (Thousand), 2015 – 2019
Figure 9–3: Brazil – Hip Fracture Patients Population (Thousand), 2010 – 2014
Figure 9–4: Brazil – Forecast for Hip Fracture Patients Population (Thousand), 2015 – 2019
Figure 9–5: Brazil – Osteoporosis Market (Million US$), 2010 – 2014
Figure 9–6: Brazil – Forecast for Osteoporosis Market (Million US$), 2015 – 2019
Figure 10–1: Russia – Osteoporosis Patients Population (Thousand), 2010 – 2014
Figure 10–2: Russia – Forecast for Osteoporosis Patients Population (Thousand), 2015 – 2019
Figure 10–3: Russia – Hip Fracture Patients Population (Thousand), 2010 – 2014
Figure 10–4: Russia – Forecast for Hip Fracture Patients Population (Thousand), 2015 – 2019
Figure 10–5: Russia – Osteoporosis Market (Million US$), 2010 – 2014
Figure 10–6: Russia – Forecast for Osteoporosis Market (Million US$), 2015 – 2019
Figure 10–7: Russia – Level of Awareness (Percent), 2010
Figure 11–1: United Kingdom – Osteoporosis Patients Population (Thousand), 2010 – 2014
Figure 11–2: United Kingdom – Forecast for Osteoporosis Patients Population (Thousand), 2015 – 2019.
Figure 11–3: United Kingdom – Hip Fracture Patients Population (Thousand), 2010 – 2014
Figure 11–4: United Kingdom – Forecast for Hip Fracture Patients Population (Thousand), 2015 – 2019
Figure 11–5: United Kingdom – Osteoporosis Market (Million US$), 2010 – 2014
Figure 11–6: United Kingdom – Forecast for Osteoporosis Market (Million US$), 2015 – 2019
Figure 12–1: France – Osteoporosis Patients Population (Thousand), 2010 – 2014
Figure 12–2: France – Forecast for Osteoporosis Patients Population (Thousand), 2015 – 2019
Figure 12–3: France – Hip Fracture Patients Population (Thousand), 2010 – 2014
Figure 12–4: France – Forecast for Hip Fracture Patients Population (Thousand), 2015 – 2019
Figure 12–5: France – Osteoporosis Market (Million US$), 2010 – 2014
Figure 12–6: France – Forecast for Osteoporosis Market (Million US$), 2015 – 2019
Figure 13–1: Germany – Osteoporosis Patients Population (Thousand), 2010 – 2014
Figure 13–2: Germany – Forecast for Osteoporosis Patients Population (Thousand), 2015 – 2019
Figure 13–3: Germany – Hip Fracture Patients Population (Thousand), 2010 – 2014
Figure 13–4: Germany – Forecast for Hip Fracture Patients Population (Thousand), 2015 – 2019
Figure 13–5: Germany – Osteoporosis Market (Million US$), 2010 – 2014
Figure 13–6: Germany – Forecast for Osteoporosis Market (Million US$), 2015 – 2019
Figure 14–1: United States – Osteoporosis Patients Population (Thousand), 2010 – 2014
Figure 14–2: United States – Forecast for Osteoporosis Patients Population (Thousand), 2015 – 2019
Figure 14–3: United States – Hip Fracture Patients Population (Thousand), 2010 – 2014
Figure 14–4: United States – Forecast for Hip Fracture Patients Population (Thousand), 2015 – 2019
Figure 14–5: United States – Osteoporosis Market (Million US$), 2010 – 2014
Figure 14–6: United States – Forecast for Osteoporosis Market (Million US$), 2015 – 2019
Figure 15–1: Worldwide – Ageing Population & Forecast (Million), 2010 – 2050
Figure 15–2: Worldwide – Life Expectancy (Year), 1990, 2000 & 2012
Figure 17–1: Merck – Osteoporosis Drugs Sales (Million US$), 2010 – 2014
Figure 17–2: Merck – Forecast for Osteoporosis Drugs Sales (Million US$), 2015 – 2019
Figure 17–3: Sanofi – Osteoporosis Drugs Sales (Million US$), 2010 – 2014
Figure 17–4: Sanofi – Forecast for Osteoporosis Drugs Sales (Million US$), 2015 – 2019
Figure 17–5: Novartis – Osteoporosis Drugs Sales (Million US$), 2010 – 2014
Figure 17–6: Novartis – Forecast for Osteoporosis Drugs Sales (Million US$), 2015 – 2019
Figure 17–7: Eli Lilly – Osteoporosis Drugs Sales (Million US$), 2010 – 2014
Figure 17–8: Eli Lilly – Forecast for Osteoporosis Drugs Sales (Million US$), 2015 – 2019
Figure 17–9: Amgen – Osteoporosis Drugs Sales (Million US$), 2010 – 2014
Figure 17–10: Amgen – Forecast for Osteoporosis Drugs Sales (Million US$), 2015 – 2019
LIST OF TABLES
Table 5–1: India – Osteoporosis Treatments & Respective Reimbursement Status, 2013
Table 6–1: China – Osteoporosis Treatments & Respective Reimbursement Status, 2013
Table 7–1: Japan – Osteoporosis Treatments & Respective Reimbursement, 2013
Table 8–1: Korea – Osteoporosis Treatments & Respective Reimbursement, 2013
Table 11–1: United Kingdom – Available Medical Interventions & Reimbursement Policies, 2013
Table 12–1: France – Available Medical Interventions & Reimbursement Policies, 2013
Table 13–1: Germany – Available Medical Interventions & Reimbursement Policies, 2013
Table 16–1: Asia Pacific – Status of Osteoporosis in NHP & Guidelines Availability, 2013
Table 5–1: India – Osteoporosis Treatments & Respective Reimbursement Status, 2013
Table 6–1: China – Osteoporosis Treatments & Respective Reimbursement Status, 2013
Table 7–1: Japan – Osteoporosis Treatments & Respective Reimbursement, 2013
Table 8–1: Korea – Osteoporosis Treatments & Respective Reimbursement, 2013
Table 11–1: United Kingdom – Available Medical Interventions & Reimbursement Policies, 2013
Table 12–1: France – Available Medical Interventions & Reimbursement Policies, 2013
Table 13–1: Germany – Available Medical Interventions & Reimbursement Policies, 2013
Table 16–1: Asia Pacific – Status of Osteoporosis in NHP & Guidelines Availability, 2013
